Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMSW) Payables (2022 - 2025)

Historic Payables for NewAmsterdam Pharma (NAMSW) over the last 4 years, with Q3 2025 value amounting to $10.1 million.

  • NewAmsterdam Pharma's Payables fell 455.58% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year decrease of 455.58%. This contributed to the annual value of $13.6 million for FY2024, which is 1958.87% down from last year.
  • NewAmsterdam Pharma's Payables amounted to $10.1 million in Q3 2025, which was down 455.58% from $9.5 million recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma's Payables ranged from a high of $22.7 million in Q2 2023 and a low of $8.0 million during Q1 2025
  • For the 4-year period, NewAmsterdam Pharma's Payables averaged around $13.0 million, with its median value being $10.4 million (2024).
  • Per our database at Business Quant, NewAmsterdam Pharma's Payables tumbled by 5510.92% in 2024 and then tumbled by 455.58% in 2025.
  • Over the past 4 years, NewAmsterdam Pharma's Payables (Quarter) stood at $18.9 million in 2022, then dropped by 10.35% to $16.9 million in 2023, then fell by 19.59% to $13.6 million in 2024, then dropped by 25.79% to $10.1 million in 2025.
  • Its last three reported values are $10.1 million in Q3 2025, $9.5 million for Q2 2025, and $8.0 million during Q1 2025.